Staar Surgical Co (NASDAQ:STAA)
| Market Cap | 1.10B-16.4% |
| Revenue (ttm) | 339.59M+51.3% |
| Net Income | 3.84M+104.0% |
| EPS | 0.08+104.1% |
| Shares Out | 49.79M |
| PE Ratio | 281.69 |
| Forward PE | 40.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,079.796 |
| Open | 22.33 |
| Previous Close | 22.36 |
| Day's Range | 22.06 - 22.60 |
| 52-Week Range | 15.59 - 35.87 |
| Beta | 1.18 |
| Analysts | Hold |
| Price Target | 30.89(+39.39%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 14 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About STAA
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
$STAA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in STAA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by STAA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
STAA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
STAA Revenue by Segment or Geography
As of: Q3 2026 (Jul 3, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New STAA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to STAA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in STAA
| ETF | Est. Holding Size |
|---|---|
| IJRiShares Core S&P Small-Cap ETF | $40.21M |
| VTIVanguard Morningstar Total Stock Market ETF | $21.45M |
| IWMiShares Russell 2000 ETF | $17.66M |
| VBVanguard Morningstar Small-Cap ETF | $15.51M |
| VXFVanguard Extended Market ETF | $13.03M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $8.86M |
Estimated from each fund’s disclosed top holdings × AUM
STAA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from STAA’s recent data — informational, not investment advice
